Misonix Reports Fourth Quarter and Fiscal Year 2009 Financi...(1280217 Goodwill ...),Health

Date:10/1/2009

1,280,217 Goodwill 5,765,698 5,784,542 Other assets 1,164,720 807,203 Assets of discontinued operations 0 27,494 ------ ------ Total assets $35,163,406 $37,250,074 =========== =========== Liabilities and stockholders' equity ------------------------------------ Current liabilities: Revolving credit facilities $4,453,950 $4,470,389 Notes payable 261,485 246,888 Accounts payable 2,978,509 5,497,541 Accrued expenses and other current liabilities 3,498,670 4,760,115 Current maturities of capital lease obligations 180,970 307,325 Current portion of deferred gain from sale and leaseback of building 1,054,543 159,195 Foreign income taxes payable 797,533 696,791 ------- ------- Total current liabilities 13,225,660 16,138,244 Capital lease obligations 27,716 225,909 Deferred gain from sale and leaseback of building 0 1,273,772 Deferred income taxes 343,454 250,514 Deferred income 308,287 371,452 Deferred lease liability 274,501 348,502 ------- ------- Total liabilities 14,179,618 18,608,393 Commitments and contingencies Minority interest
'/>"/>

SOURCE Misonix, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine technology :

1. Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Spherix Reports Second Quarter Earnings
4. Tapestry Reports Second Quarter 2007 Results
5. Callisto Reports on Second-Quarter 2007 Milestones
6. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
7. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
8. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
9. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
10. Biopure Reports on Meeting with the FDA
11. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors